The Alliance for Pharmacy Compounding has launched a free tool for connecting hospitals with 503B outsourcing facilities, or alternatively, 503A sterile compounding pharmacies, that can supply shortage drugs to treat COVID-19.
Novel Coronavirus (COVID-19) News
Below are links to AHA Today stories on novel coronavirus (COVID-19). For all coronavirus resources and news updates, visit our COVID-19 page.
Latest
A new AHA resource examines the impact of the social determinants of health on patients and communities as they battle the COVID-19 outbreak.
From every corner of society, people are demonstrating a desire to help keep our health care workforce safe, write Priya Bathija, AHA vice president of strategic initiatives, and Mike Schiller, director, supply chain for The Association for Health Care Resource & Materials Management.
The Centers for Disease Control and Prevention released guidance for health care providers who care for breastfeeding women and infants who receive breast milk, based on what is currently known about the virus that causes COVID-19 and the transmission of other viral respiratory pathogens.
The Health Resources and Services Administration April 30 at 2 p.m. ET will host a webinar for health care providers on the agency’s COVID-19 Uninsured Program Portal.
The National Institutes of Health urged scientists and inventors with a rapid testing technology to compete for a share of $500 million in funding to develop accurate at-home and point-of-care diagnostic tests, with the goal to make millions of tests available per week by the end of summer and even more in time for the flu season.
Two rural hospital leaders share how they are addressing the coronavirus pandemic in their communities.
In this AHA blog, Priya Bathija, AHA vice president of strategic initiatives, and Mike Schiller, director, supply chain for The Association for Health Care Resource & Materials Management, share examples of businesses, manufacturers and individuals who are finding important new ways to support our COVID-19 caregivers.
Members of the Partnership to Amend 42 CFR Part 2, including the AHA, urged the Department of Health and Human Services to issue a rule as soon as possible on the Part 2 provisions in the Coronavirus Aid, Relief, and Economic Safety Act.
Health experts agree that telemedicine’s ability to bring virtual expertise to bedsides everywhere is a vital tool for fighting COVID-19.
The AHA’s Institute for Diversity and Health Equity released a new resource highlighting steps hospitals can and are taking to address disparities that arise during the fight against COVID-19.
The Food and Drug Administration has updated and reissued its April 18 emergency use authorization on face masks for the general public to clarify that non-surgical face masks are not intended for use by health care personnel as personal protective equipment, meaning they are not a substitute for respirator or surgical masks.
The Substance Abuse and Mental Health Services Administration awarded $450 million in grants, including $250 million in emergency COVID-19 funding, to expand access to mental health and substance use disorder treatment services through certified community behavioral health clinics.
The Department of Labor’s Occupational Safety and Health Administration issued interim guidance on the reuse and decontamination of N95 and other filtering-facepiece respirators during the COVID-19 pandemic.
A coalition of more than 30 groups led by the AHA, the U.S. Chamber of Commerce and America’s Health Insurance Plans urged Congress to take swift action to protect Americans’ health care coverage in its response to the COVID-19 crisis.
The Trump administration put forward a series of guidelines for testing and rapid response programs in anticipation of reopening the nation’s economy.
The Food and Drug Administration April 24 reminded health care providers of the need to closely monitor patients for serious and potentially life-threatening side effects of hydroxychloroquine and chloroquine when used off-label to treat COVID-19.
The AHA has been featured in numerous media publications, including the Washington Post, Wall Street Journal, Politico and Modern Healthcare, for various COVID-19 content.
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM) Model, due to COVID-19.